21.co Integrates Chainlink Proof of Reserve To Increase Transparency of its Wrapped Bitcoin (21BTC) on Solana and Ethereum
September 23, 2024 12:00 ET
|
21Shares
ZURICH, 23 September 2024 – 21.co, the parent company of 21Shares – one of the world’s largest issuers of crypto exchange traded products (ETPs), today announced the integration of the...
WHO endorses dual-stain cytology (CINtec PLUS) testing in its cervical cancer prevention guidelines, advancing patient care and underlining Roche’s role in pioneering cervical cancer solutions
September 23, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
Roche’s CINtec PLUS Cytology is the only FDA-approved and CE-marked dual-stain test to triage human papillomavirus (HPV)-positive cervical cancer screening test results Dual-stain biomarkers aid in...
Basilea schliesst Vereinbarung mit BARDA zur Entwicklung neuartiger Medikamente für die Behandlung von Infektionen durch Pilze und Bakterien ab und erhält erste Förderung
September 19, 2024 01:15 ET
|
Basilea Pharmaceutica AG, Allschwil
Bereitstellung eines ersten Betrags von USD 29 Mio. zur Unterstützung der Entwicklung von Basileas klinischen First-in-Class Antipilzmitteln Fosmanogepix und BAL2062Mehrjähriges Other Transaction...
Basilea enters into agreement with BARDA to develop novel antifungals and antibacterials and receives initial funding
September 19, 2024 01:15 ET
|
Basilea Pharmaceutica AG, Allschwil
Initial funding of USD 29 million to support development of Basilea’s clinical stage first-in-class antifungals, fosmanogepix and BAL2062Multi-year Other Transaction Agreement (OTA) allows for...
Addex Provisional 2024 Half-Year and Second Quarter Result increased from a Net loss to a Net Profit
September 19, 2024 01:00 ET
|
Addex Therapeutics
Ad Hoc Announcement Pursuant to Art. 53 LR Geneva, Switzerland, September 19, 2024 - Addex Therapeutics (SIX/NASDAQ: ADXN), a clinical-stage biopharmaceutical company focused on developing a...
Positive phase III results show Xofluza significantly reduces the transmission of influenza viruses
September 19, 2024 01:00 ET
|
F. Hoffmann-La Roche Ltd
Data from the CENTERSTONE study shows single-dose Xofluza reduces transmission of influenza from an infected person to household membersThis is the first time that any antiviral used in the treatment...
EPH European Property Holdings PLC announces Profit Warning - EPH expects a significantly lower loss in its consolidated accounts for the 1HY 2024 compared to the previous year
September 18, 2024 12:30 ET
|
EPH European Property Holdings PLC
18 September 2024, Limassol, Cyprus I Ad hoc announcement pursuant to Art. 53 LR EPH European Property Holdings PLC (“EPH”, the “Company”) would like to announce that the Company expects a loss of...
FDA approves Novartis Kisqali® to reduce risk of recurrence in people with HR+/HER2- early breast cancer
September 17, 2024 12:55 ET
|
Novartis Pharma AG
Ad hoc announcement pursuant to Art. 53 LR Broad indication in HR+/HER2- stage II and III early breast cancer (EBC) at high risk of recurrence approximately doubles population eligible for...
Idorsia continues to further the science of sleep and insomnia with new daridorexant data and analyses published at Sleep Europe 2024
September 17, 2024 11:45 ET
|
Idorsia Pharmaceuticals Ltd
Allschwil, Switzerland – September 17, 2024 Idorsia Ltd (SIX: IDIA) today announced that new data and analyses of daridorexant, Idorsia’s dual orexin receptor antagonist for the treatment of adults...
Clariant sells the real estate property “Industrial Park Fechenheim”
September 17, 2024 01:00 ET
|
Clariant International Ltd
AD HOC ANNOUNCEMENT PURSUANT TO ART. 53 LR MUTTENZ, 17 SEPTEMBER 2024 Clariant, a sustainability-focused specialty chemical company, today announced that it has reached an agreement to...